BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension (BEET-PAH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02000856 |
Recruitment Status :
Completed
First Posted : December 4, 2013
Last Update Posted : March 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Arterial Hypertension | Dietary Supplement: Beetroot juice | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension |
Study Start Date : | November 2013 |
Actual Primary Completion Date : | February 2015 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Nitrate rich beetroot juice
Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
|
Dietary Supplement: Beetroot juice |
Placebo Comparator: Nitrate depleted beetroot juice
Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
|
Dietary Supplement: Beetroot juice |
- Change in VO2 submax and or VO2 max [ Time Frame: 7 days ]
- Change in 6MWT [ Time Frame: 7 days ]
- Change in WHO functional class [ Time Frame: 7 days ]
- Change in echocardiographic parameters [ Time Frame: 7 days ]Change in; pulmonary artery systolic pressure (PASP), ventricular diastolic function, systolic right and left ventricular function, right and left atrial/ventricular dimensions will be calculated
- Change in exhaled NO [ Time Frame: 7 days ]
- Change in systemic bloodpressure [ Time Frame: 7 days ]
- Change in metabolic pathways involved in nitric oxide production and regulation [ Time Frame: 7 days ]Change in the following biochemical variables will be calculated; ADMA, SDMA, Arginine, Citrulline, Ornithine, uric acid, nitrate, nitrite
- Change in NT-pro-BNP [ Time Frame: 7 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- PAH (pulmonary arterial hypertension)
- WHO functional class II-III
Exclusion Criteria:
- WHO functional class I or IV
- pregnancy
- known intolerance or allergy to beetroot
- treatment with Allopurinol
- treatment with Iloprost (inhaled)
- systolic bloodpressure < 95 mmHg
- diabetes mellitus type 2

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000856
Sweden | |
Uppsala University Hospital | |
Uppsala, Sweden |
Principal Investigator: | Gerhard Wikström, MD, PhD | Uppsala University and Uppsala University Hospital |
Responsible Party: | Uppsala University |
ClinicalTrials.gov Identifier: | NCT02000856 |
Other Study ID Numbers: |
BEET-PAH |
First Posted: | December 4, 2013 Key Record Dates |
Last Update Posted: | March 27, 2018 |
Last Verified: | March 2018 |
Pulmonary Arterial Hypertension Familial Primary Pulmonary Hypertension Hypertension Vascular Diseases |
Cardiovascular Diseases Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases |